Press Release

June 22, 2022
1 min read

CMS issues permanent J-code for Xipere


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CMS has issued a permanent product-specific J-code for Xipere, Bausch + Lomb announced in a press release.

Xipere (triamcinolone acetonide injectable suspension) is set to have the code J3299, which will become effective July 1.

Xipere is used to treat patients with macular edema associated with uveitis by utilizing the suprachoroidal space.

“At Bausch + Lomb we are committed to bringing new and innovative therapies to market that benefit eye care professionals and the patients they serve. This not only applies to the development of new therapies, but also making these therapies accessible once they become available,” Yolande Barnard, senior vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in the release. “The issuance of the permanent J-code will help facilitate access to Xipere for Americans suffering from macular edema associated with uveitis and help streamline the reimbursement process.”

The FDA approved Xipere in October 2021.